Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: The non-randomised ISID study

IGOS Consortium

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Scopus)

Abstract

Objective To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses. Methods From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression. Results Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an α early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a α late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course. Conclusions This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.

Original languageEnglish
Article number321496
Pages (from-to)113-121
Number of pages9
JournalJournal of neurology, neurosurgery, and psychiatry
Volume91
Issue number2
Early online date5 Oct 2019
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • Guillain-Barré syndrome
  • poor prognosis
  • second IVIg course
  • treatment

Cite this